Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
A Placebo-Controlled, Double-Blind, Randomized, Multicenter Study To Assess The Effects Of Dronedarone 400 Mg Twice Daily For 12 Weeks On Atrial Fibrillation Burden In Subjects With Permanent Pacemakers, Michael D. Ezekowitz, Kenneth Ellenbogen , M.D., John P. Dimarco, Karoly Kaszala, Alexander Boddy, Gregory Geba P., Andrew Koren
A Placebo-Controlled, Double-Blind, Randomized, Multicenter Study To Assess The Effects Of Dronedarone 400 Mg Twice Daily For 12 Weeks On Atrial Fibrillation Burden In Subjects With Permanent Pacemakers, Michael D. Ezekowitz, Kenneth Ellenbogen , M.D., John P. Dimarco, Karoly Kaszala, Alexander Boddy, Gregory Geba P., Andrew Koren
Human and Molecular Genetics Publications
Purpose
Dronedarone is a benzofuran derivative with a pharmacological profile similar to amiodarone but has a more rapid onset of action and a much shorter half-life (13–19 h). Our goal was to evaluate the efficacy of dronedarone in atrial fibrillation (AF) patients using dual-chamber pacemakers capable of quantifying atrial fibrillation burden.
Methods
Pacemakers were adjusted to optimize AF detection. Patients with AF burden >1 % were randomized to dronedarone 400 mg twice daily (BID) or placebo. Pacemakers were interrogated after 4 and 12 weeks of treatment. The primary endpoint was the change in AF burden from baseline over the 12-week …